United Therapeutics (NASDAQ:UTHR) Hits New 1-Year High – What’s Next?

Shares of United Therapeutics Co. (NASDAQ:UTHR) reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $399.62 and last traded at $397.92, with a volume of 11479 shares trading hands. The stock had previously closed at $397.49.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on the company. Argus increased their price objective on United Therapeutics from $360.00 to $400.00 and gave the company a “buy” rating in a report on Thursday, October 31st. The Goldman Sachs Group lifted their price objective on United Therapeutics from $243.00 to $302.00 and gave the stock a “neutral” rating in a research note on Friday, November 1st. Bank of America decreased their target price on shares of United Therapeutics from $303.00 to $280.00 and set an “underperform” rating for the company in a research report on Thursday, August 1st. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $350.00 to $380.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 20th. Finally, Oppenheimer increased their price objective on shares of United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $370.86.

United Therapeutics Trading Up 1.4 %

The firm has a market cap of $17.99 billion, a price-to-earnings ratio of 17.46, a P/E/G ratio of 1.08 and a beta of 0.56. The firm’s 50-day moving average is $357.42 and its 200-day moving average is $320.37.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported $6.39 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.16 by $0.23. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm had revenue of $748.90 million during the quarter, compared to analysts’ expectations of $722.62 million. During the same period last year, the company earned $5.38 earnings per share. The business’s revenue was up 22.9% on a year-over-year basis. Analysts forecast that United Therapeutics Co. will post 25.57 EPS for the current fiscal year.

Insider Transactions at United Therapeutics

In related news, CEO Martine A. Rothblatt sold 269 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total transaction of $93,722.29. Following the completion of the sale, the chief executive officer now owns 130 shares in the company, valued at approximately $45,293.30. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $344.18, for a total value of $1,239,048.00. Following the transaction, the chief executive officer now owns 130 shares in the company, valued at $44,743.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 269 shares of United Therapeutics stock in a transaction on Monday, August 26th. The stock was sold at an average price of $348.41, for a total value of $93,722.29. Following the sale, the chief executive officer now owns 130 shares in the company, valued at $45,293.30. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 81,422 shares of company stock valued at $29,229,828 over the last ninety days. 11.90% of the stock is currently owned by insiders.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in the business. ClariVest Asset Management LLC boosted its stake in United Therapeutics by 120.0% in the second quarter. ClariVest Asset Management LLC now owns 77 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 42 shares during the last quarter. USA Financial Formulas purchased a new position in United Therapeutics during the third quarter valued at approximately $33,000. V Square Quantitative Management LLC purchased a new position in shares of United Therapeutics during the 2nd quarter valued at $30,000. Innealta Capital LLC bought a new position in United Therapeutics in the 2nd quarter worth about $33,000. Finally, Capital Performance Advisors LLP purchased a new stake in United Therapeutics in the third quarter valued at approximately $82,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.